-
Uncategorized2 weeks agoFirst patient dosed in trial of Geographic Atrophy treatment
The first patient has been dosed in a first-in-human clinical trial of a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). CTx001, developed...
-
Uncategorized2 weeks agoMHRA to offer early review of non-animal data
The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in...
-
Uncategorized2 weeks agoSygnature Discovery appoints new Head of In Vivo Pharmacology
CRO Sygnature Discovery has announced the appointment of Susanne Back as Head of In Vivo Pharmacology. Back has 20 years of in vivo pharmacology experience across academia and industry, including...
-
Uncategorized2 weeks ago
Takeda clears path to FDA with phase 3 data on $4B psoriasis bet
Takeda has posted phase 3 data on an autoimmune asset it acquired for $4 billion, laying down a marker ahead of a fight for market share...
-
Uncategorized2 weeks agoRadspherin receives patent protection in China
The China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin, a radiopharmaceutical treating micrometastases in cancer patients. Radspherin, developed by biotechnology company...
-
Uncategorized2 weeks ago
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
While participants on a lower dose of Wave Life Sciences’ RNA therapy lost 5.3% total fat at the six-month mark, those receiving the higher dose saw...
-
Uncategorized2 weeks agoGlobal collaboration aims to create safer cancer therapeutics
An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics. iXCells Biotechnologies, a provider of...
-
Uncategorized2 weeks ago
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data
Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair.
-
Uncategorized2 weeks ago
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA’s Hunter Syndrome Nod
Avlayah is the first Hunter syndrome therapy approved to address the condition’s neurologic complications, according to Tracy Beth Høeg, acting director of the Center for Drug...
-
Uncategorized2 weeks ago
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
Biomarker data for Sarepta Therapeutics’ RNA programs, licensed from Arrowhead Pharmaceuticals, are “competitive” and “strong,” according to analysts at Jefferies, which projected over $1 billion in...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
